Case Studies

Craig I. Coleman, PharmD, and Christine G. Kohn PharmD Candidate
Published Online: Monday, July 11, 2011
Follow Pharmacy_Times:

Case One

MK, a 68-year-old man, was discharged from the hospital after a myocardial infarction (MI) 2 weeks ago. At this routine office visit, MK is diagnosed with depression. His doctor considers prescribing a tricyclic antidepressant (TCA), but contacts his community pharmacist for a recommendation.

What should the pharmacist recommend to manage MK's post-MI depression?

Case Two

SL, a 25-year-old woman, presents to the clinic complaining of an increased frequency and urgency to urinate and dysuria over the past 3 days. She has no fever or flank pain and does not have a recent history of urinary tract infections (UTIs). A urine dipstick is positive for leukocyte esterase, white blood cells, and nitrates. Based upon the above symptoms and test results, and the fact that SL has no known urologic abnormalities, her doctor diagnoses her with an uncomplicated UTI. SL's doctor considers prescribing a fluoroquinolone, but asks you, the pharmacist, for a recommendation. SL has no known drug allergies.

How should the pharmacist handle this prescription?




Dr. Coleman is associate professor of pharmacy practice and director of the pharmacoeconomics and outcomes studies group at the University of Connecticut School of Pharmacy.  Ms. Kohn is a PharmD candidate from the University of Connecticut School of Pharmacy. 

Related Articles
A pharmacy school team nabbed second place in the Mississippi Public Universities’ Blueprint Mississippi Social Business Challenge.
A study published in the February 2015 issue of Infection Control & Hospital Epidemiology found that antibiotics were inappropriately prescribed to 45% of patients with respiratory tract infections in an outpatient setting.
Treating traveler’s diarrhea with antibiotics may contribute to antibiotic resistance and spread resistant bacteria strains, particularly if travelers visit developing parts of the world.
Because upper respiratory tract infections cost $40 billion annually in the United States, even a small reduction in incidence would have significant economic consequences.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times